克洛皮多格勒与间歇性肺部疾病的关联:通过日本药监数据库获得洞察力
Mariko Kozaru1, Hiroko Kambara1, Akari Higuchi1
1Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-1094, Japan.
克洛皮多格雷尔和普拉苏格雷尔,P2Y12抑制剂,显示出不同的不良事件概况. 克洛皮多格雷尔的使用与意外事件有关,如肺部疾病和肝脏问题,与普拉苏格雷尔不同.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药品安全 药品安全
背景情况:
- 经常处方P2Y12受体抑制剂克洛皮多格雷尔和普拉苏格雷尔.
- 它们独特的代谢途径表明了不良事件 (AE) 概况的潜在差异,这些概况仍然不清楚.
研究的目的:
- 为了比较由克洛皮多格雷尔和普拉苏格雷尔诱导的不良事件 (AEs).
- 在自发报告数据库中对每个药物报告的副作用进行排名.
主要方法:
- 对日本药物不良事件报告数据库 (JADER) 的分析.
- 计算报告几率比率 (ROR) 和95%置信区间 (CI) 对于与克洛皮多格雷尔和普拉苏格雷尔相关的副作用.
主要成果:
- 总共分析了5869份克洛皮多格雷尔和513份普拉苏格雷尔报告,分别确定了703个和135个不同的副作用.
- 两种药物中,出血并发症是常见的.
- 克洛皮多格雷尔的意想不到的副作用包括间歇性肺病,肝功能异常和肝细胞损伤,这些对普拉苏格雷尔来说并不突出.
结论:
- 这种药监数据库分析显示了克洛皮多格雷尔和普拉苏格雷尔的不同的AE概况.
- 确定了与克洛皮多格雷尔相关的意想不到的副作用,为临床监测和患者安全提供了洞察力.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
